Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Sponsor
Alcon Research (Industry)
Overall Status
Completed
CT.gov ID
NCT00346866
Collaborator
(none)
136
1
19
7.1

Study Details

Study Description

Brief Summary

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Condition or Disease Intervention/Treatment Phase
  • Drug: anecortave acetate
Phase 2

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Study Start Date :
May 1, 2000
Actual Primary Completion Date :
Dec 1, 2001
Actual Study Completion Date :
Dec 1, 2001

Outcome Measures

Primary Outcome Measures

  1. Mean change from the baseline in logMAR visual acuity score at Month 6 []

Secondary Outcome Measures

  1. % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV. []

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • AMD disease
Exclusion Criteria:
  • Age

Contacts and Locations

Locations

Site City State Country Postal Code
1 Facility Beachwood Ohio United States 44122

Sponsors and Collaborators

  • Alcon Research

Investigators

  • Study Director: Patricia Zilliox, Alcon Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00346866
Other Study ID Numbers:
  • C-00-07
First Posted:
Jun 30, 2006
Last Update Posted:
Aug 5, 2008
Last Verified:
Aug 1, 2008
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 5, 2008